{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349198","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2026-08-13T20:11:18+00:00","discovered_at":"2026-08-13T20:13:00.258618+00:00","generated_at":"2026-08-13T20:13:16.626288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Assembly Bio Q2 net loss narrows to $3.9M; cash $320M, pipeline advances","bullets":["Q2 2026 net loss $3.9M ($0.20/share) vs $10.2M ($1.33) in Q2 2025; revenue from Gilead $13.4M incl. $5.1M catch-up.","Cash $320.4M at June 30, up from $226.6M; $115M gross financing completed; runway into 2029 incl. $75M Gilead fee due Q4 2026.","ABI-6250 expanded into cholestatic liver diseases (PBC, PSC); Phase 2 study expected Q1 2027.","GS-1179 selected for HSV HPI program; Phase 2 initiation expected by year-end 2026; opt-in decision on 40% U.S. cost-profit share by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349198","json":"https://secwatch.observer/filing/0001193125-26-349198.json","markdown":"https://secwatch.observer/filing/0001193125-26-349198.md","text":"https://secwatch.observer/filing/0001193125-26-349198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/0001193125-26-349198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/asmb-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:13:16.626288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}